Innovative High Containment Pharmaceutical Sieving System from Russell Finex

whitePaper | April 7, 2022

The United States defines a rare disease as a condition affecting fewer than 200,000 people in the country or one in which “there is no reasonable expectation” of recovering research and development costs.1 Examples of rare diseases include genetically-linked cancers, cystic fibrosis, and debilitating pediatric conditions like Gaucher disease and spinal muscular atrophy

whitePaper | February 16, 2023

Flexible and cost-effective, single-use technologies offer biopharmaceutical companies a way to transform their biologics production and meet the growing demand for these life-changing therapies.

whitePaper | December 13, 2022

A recent e-symposium presented insights into the latest research and innovative solutions to help shorten timeto-market, reduce development costs, increase yield, and assure quality and pharmacopoeia compliance throughout the drug development process.

whitePaper | July 8, 2022

Particulates are ubiquitous in parenteral drug products and remain a concern throughout their development and production1–3. These particles must be monitored to satisfy.

whitePaper | May 5, 2022

welcome to pharmaprojects'2022 review of trends in pharmaceutical R&D for 30 year now, I've been taking an anual look at the evloution of pharma

whitePaper | February 24, 2023

The WBR Insights research team surveyed 100 leaders from pharmaceutical companies to generate the results featured in this report. The respondents occupy roles in marketing, sales, commercial strategy, and product development.